Viela Bio (VIE) Misses Q1 EPS by 8c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. AMD
2. BKNG
3. DOX
4. AMGN
5. DUOL
6. ANET
7. SWKS
8. CVS
9. SPY
10. XYZ

Go back to Viela Bio (VIE) Misses Q1 EPS by 8c

Viela Bio Reports First Quarter 2020 Financial Results and Program Highlights

May 13, 2020 4:16 PM EDT

Company to host investor conference call and webcast today at 5:00 pm ET

GAITHERSBURG, Md., May 13, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq: VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory disease, today reported financial results and provided program highlights for the first quarter ended March 31, 2020.

With the PDUFA date for our lead product candidate, inebilizumab, approaching in about one month, we are nearing another major company milestoneour first potential U.S. regulatory approval, said Bing Yao, Ph.D., Chief Executive Officer at Viela Bio. In anticipation,... More